Bharat Biotech Made Nasal Vaccine SaNotize Gets Approval From Centre
The drug controller has approved Bharat Biotech's nasal vaccine against Kovid-19 for use in emergency scenarios. This information was provided by Union Health Minister Mansukh Mandaviya in a tweet. "India has made full use of its science, research and development-human resources under the leadership of Prime Minister Narendra Modi," the Health Minister stated.
Big Boost to India's Fight Against COVID-19!— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022
Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.
In February, Mumbai-based Glenmac, in collaboration with SaNotize Company, introduced a nasal spray in India for the treatment of adult Covid patients. The Drugs Controller General of India has approved manufacturing and marketing. "Phase III studies in India have been largely successful, with viral load lowered by 94 percent in 24 hours and 99 percent in 48 hours," according to the official release. There has been a drop of up to percentage points.
There has been a significant drop in new instances of corona infection in the country in recent years. The number of corona virus infection cases in India has risen to 4,44,66,862 with the arrival of 4,417 new cases in the last 24 hours. The number of new cases of infection is at its lowest in three months. According to the Union Health Ministry's most recent figures, as of 8 a.m. on Tuesday, the death toll has risen to 5,28,030 due to the loss of 23 additional patients due to infection. Kerala has reconciled one of the new incidents of death. The number of cases being treated in the country has been reduced to 52,336. On June 6, there were 3,714 new cases recorded in the country.